Drug intelligence / Profile preview

Cannabalance

Development stage: Unknown
Lead developer: Kensana Health
Modality: Small Molecules
Administration: Topical

Overview

Cannabalance is a full-spectrum phytopharmaceutical cannabinoid product developed by Kensana Health for general wellness and over-the-counter (OTC) indications. It targets the endocannabinoid system (ECS) to provide therapeutic benefits. The product is formulated using proprietary phyto micro-encapsulation technology, developed in collaboration with Cannasoul, to optimize delivery and bioavailability. It is currently being evaluated in a Phase 1/2 clinical trial in Australia for general wellness and other OTC-related indications.

Brand names: Cannabalance
Other names: Cannabalance OTC CBD Product

Beyond the preview

Go deeper on Cannabalance.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cannabalance.

Explore the full profile